Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Sensus Healthcare (SRTS) over the last 9 years, with Q2 2025 value amounting to $5000.0.

  • Sensus Healthcare's Share-based Compensation rose 40000.0% to $5000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $206000.0, marking a year-over-year increase of 4305.56%. This contributed to the annual value of $323000.0 for FY2024, which is 152.44% down from last year.
  • As of Q2 2025, Sensus Healthcare's Share-based Compensation stood at $5000.0, which was up 40000.0% from $79000.0 recorded in Q1 2025.
  • Sensus Healthcare's Share-based Compensation's 5-year high stood at $204000.0 during Q3 2021, with a 5-year trough of $1000.0 in Q2 2023.
  • Over the past 5 years, Sensus Healthcare's median Share-based Compensation value was $59000.0 (recorded in 2021), while the average stood at $70266.7.
  • As far as peak fluctuations go, Sensus Healthcare's Share-based Compensation skyrocketed by 45135.14% in 2021, and later crashed by 8039.22% in 2022.
  • Quarter analysis of 5 years shows Sensus Healthcare's Share-based Compensation stood at $90000.0 in 2021, then plummeted by 44.44% to $50000.0 in 2022, then increased by 4.0% to $52000.0 in 2023, then soared by 134.62% to $122000.0 in 2024, then tumbled by 95.9% to $5000.0 in 2025.
  • Its Share-based Compensation was $5000.0 in Q2 2025, compared to $79000.0 in Q1 2025 and $122000.0 in Q4 2024.